Biblioteca Virtual em Saúde

Pesquisa | Influenza A (H1N1)

  • BIREME | OPAS | OMS logo
 

Histórico de pesquisa  ()

Sua seleção  ()

 0 documento(s) selecionado(s).

Refine sua pesquisa

Collapse All  Ocultar
Expand All  Mostrar
Tipo
Áreas temáticas
Texto completo (267)
Idioma
Ano de publicação

Enviar por email

Você tem 0 documento(s) selecionado(s).

Nenhum documento selecionado

 
Resultados  1-12 de 374
1.

Polygalasaponin F treats mice with pneumonia induced by influenza virus.

Autor(es): Ye, Yi; Wang, Huixian; Liu, Jinyuan; Zhao, Fang; Xu, Peiping
Fonte: Inflammopharmacology;28(1): 299-310, 2020 Feb.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 31446589
Resumo: BACKGROUND: Influenza is an acute viral respiratory illness that causes high morbidity and mortality globally. Therapeutic actions are limited to vaccines and a few anti-viral drugs. Polygala (P.) japonica herba is rich in Polygalasaponin F (PSF, C53H86O23), used for acute bronchitis, pharyngitis, pneumonia, amygdalitis, and respiratory tract infections treatment in China. Hypercytokinemia is often correlated with severe pneumonia caused by several influenza viruses. PSF was reported to hav (mais)
2.

IRE1 Signaling As a Putative Therapeutic Target in Influenza Virus-induced Pneumonia.

Autor(es): Schmoldt, Carole; Vazquez-Armendariz, Ana Ivonne; Shalashova, Irina; Selvakumar, Balachandar; Bremer, Corinna M; Peteranderl, Christin; Wasnick, Roxana; Witte, Biruta; Gattenlöhner, Stefan; Fink, Ludger; Vadász, István; Morty, Rory E; Pleschka, Stephan; Seeger, Werner; Günther, Andreas; Herold, Susanne
Fonte: Am J Respir Cell Mol Biol;61(4): 537-540, 2019 10.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 31573336
3.

Combined immunization with attenuated live influenza vaccine and chimeric pneumococcal recombinant protein improves the outcome of virus-bacterial infection in mice.

Autor(es): Kramskaya, T; Leontieva, G; Desheva, Yu; Grabovskaya, K; Gupalova, T; Rudenko, L; Suvorov, A
Fonte: PLoS One;14(9): e0222148, 2019.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 31513620
Resumo: Influenza and its bacterial complications are a leading cause of morbidity and mortality worldwide. The effect of combined immunization with live influenza vaccine and recombinant chimeric pneumococcal protein in dual infection caused by influenza H1N1 and S. pneumoniae (serotype 3) has been studied. The combined vaccine consisted of the strain A/California/2009/38 (H1N1) pdm and chimeric recombinant protein PSPF composed of immunodominant fragments of the surface virulence factors of S. pn (mais)
4.

Oseltamivir resistance in severe influenza A(H1N1)pdm09 pneumonia and acute respiratory distress syndrome: a French multicenter observational cohort study.

Autor(es): Behillil, Sylvie; May, Faten; Fourati, Slim; Luyt, Charles-Edouard; Chicheportiche, Thomas; Sonneville, Romain; Tandjaoui-Lambiotte, Yacine; Roux, Damien; Guérin, Laurent; Mayaux, Julien; Maury, Eric; Ferré, Alexis; Georger, Jean-François; Voiriot, Guillaume; Enouf, Vincent; van der Werf, Sylvie; Mekontso Dessap, Armand; de Prost, Nicolas
Fonte: Clin Infect Dis;2019 09 20.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 31538643
Resumo: In a multicenter cohort study including 22 oseltamivir-treated patients with influenza A(H1N1)pdm09 acute respiratory distress syndrome, prevalence of the H275Y substitution in the neuraminidase, responsible for highly reduced sensitivity to oseltamivir, was 23%. Patients infected with the H275Y mutant virus had higher day-28 mortality than others (80% vs 12%; p=0.011).
5.

Statins and outcomes of hospitalized patients with laboratory-confirmed 2017-2018 influenza.

Autor(es): Atamna, Alaa; Babitch, Tanya; Bracha, Mayaan; Sorek, Nadav; Haim, Ben-Zvi; Elis, Avishay; Bishara, Jihad; Avni, Tomer
Fonte: Eur J Clin Microbiol Infect Dis;38(12): 2341-2348, 2019 Dec.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 31463620
Resumo: No studies evaluating the association between statins and outcomes of patients with seasonal influenza have been performed since the 2007-2008 and the 2009 pandemic H1N1 influenza seasons. All consecutive hospitalized patients between October 2017 and April 2018, diagnosed with laboratory-confirmed influenza A and B virus, were included. Patients were divided into two groups: statin and non-statin users. Outcomes were 30- and 90-day mortality, complications (pneumonia, myocarditis, encephal (mais)
6.

[Clinical analysis of seven cases of H1N1 influenza-associated encephalopathy in children].

Autor(es): Li, X F; Ai, B; Ye, J W; He, D M; Tan, L M; Chen, M X; Yang, H M; Zeng, F S; Yang, F X; Liu, H S; Xu, Y
Fonte: Zhonghua Er Ke Za Zhi;57(7): 538-542, 2019 Jul 02.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 31269554
Resumo: Objective: To investigate the clinical manifestations, diagnosis, and treatment of H1N1 influenza A-associated encephalopathy (IAE) in children. Methods: The clinical manifestations, laboratory tests, cranial magnetic resonance imaging (MRI), electroencephalography (EEG) examinations and treatments of seven children with H1N1 IAE hospitalized in Guangzhou Women and Children's Medical Center from December 2018 to January 2019 were retrospectively analyzed. Results: Five of the seven children (mais)
7.

Severe influenza: overview in critically ill patients.

Autor(es): Sarda, Cristina; Palma, Pedro; Rello, Jordi
Fonte: Curr Opin Crit Care;25(5): 449-457, 2019 10.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 31313681
Resumo: PURPOSE OF REVIEW: Overview of influenza infection, focusing on outcome and complications in critically ill patients. We also discuss relevant elements in immunopathogenesis and their role as predictors of severity. RECENT FINDINGS: Pandemic influenza A (H1N1) virus circulates seasonally and remains the predominant subtype among intensive care patients. Mortality in acute respiratory failure (ARF) is around 20%, independent of influenza subtypes. During severe infection, the imbalance betwe (mais)
8.

Update: Influenza Activity in the United States During the 2018-19 Season and Composition of the 2019-20 Influenza Vaccine.

Autor(es): Xu, Xiyan; Blanton, Lenee; Elal, Anwar Isa Abd; Alabi, Noreen; Barnes, John; Biggerstaff, Matthew; Brammer, Lynnette; Budd, Alicia P; Burns, Erin; Cummings, Charisse N; Garg, Shikha; Kondor, Rebecca; Gubareva, Larisa; Kniss, Krista; Nyanseor, Sankan; O'Halloran, Alissa; Rolfes, Melissa; Sessions, Wendy; Dugan, Vivien G; Fry, Alicia M; Wentworth, David E; Stevens, James; Jernigan, Daniel
Fonte: MMWR Morb Mortal Wkly Rep;68(24): 544-551, 2019 Jun 21.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 31220057
Resumo: Influenza activity* in the United States during the 2018-19 season (September 30, 2018-May 18, 2019) was of moderate severity (1). Nationally, influenza-like illness (ILI)† activity began increasing in November, peaked during mid-February, and returned to below baseline in mid-April; the season lasted 21 weeks,§ making it the longest season in 10 years. Illness attributed to influenza A viruses predominated, with very little influenza B activity. Two waves of influenza A were notable duri (mais)
9.

Combination Therapy Targeting Platelet Activation and Virus Replication Protects Mice against Lethal Influenza Pneumonia.

Autor(es): Pulavendran, Sivasami; Rudd, Jennifer M; Maram, Prasanthi; Thomas, Paul G; Akhilesh, Ramachandran; Malayer, Jerry R; Chow, Vincent T K; Teluguakula, Narasaraju
Fonte: Am J Respir Cell Mol Biol;61(6): 689-701, 2019 12.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 31070937
Resumo: Excessive neutrophils recruited during influenza pneumonia contribute to severe lung pathology through induction of neutrophil extracellular traps (NETs) and release of extracellular histones. We have recently shown that activation of platelets during influenza enhances pulmonary microvascular thrombosis, leading to vascular injury and hemorrhage. Emerging evidence indicates that activated platelets also interact with neutrophils, forming neutrophil-platelet aggregates (NPAs) that contribut (mais)
10.

Update: Influenza Activity - United States, September 30, 2018-February 2, 2019.

Autor(es): Blanton, Lenee; Dugan, Vivien G; Abd Elal, Anwar Isa; Alabi, Noreen; Barnes, John; Brammer, Lynnette; Budd, Alicia P; Burns, Erin; Cummings, Charisse N; Garg, Shikha; Garten, Rebecca; Gubareva, Larisa; Kniss, Krista; Kramer, Natalie; O'Halloran, Alissa; Reed, Carrie; Rolfes, Melissa; Sessions, Wendy; Taylor, Calli; Xu, Xiyan; Fry, Alicia M; Wentworth, David E; Katz, Jacqueline; Jernigan, Daniel
Fonte: MMWR Morb Mortal Wkly Rep;68(6): 125-134, 2019 Feb 15.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 30763296
Resumo: CDC collects, compiles, and analyzes data on influenza activity and viruses in the United States. During September 30, 2018-February 2, 2019,* influenza activity† in the United States was low during October and November, increased in late December, and remained elevated through early February. As of February 2, 2019, this has been a low-severity influenza season (1), with a lower percentage of outpatient visits for influenza-like illness (ILI), lower rates of hospitalization, and fewer dea (mais)
11.

Making Universal Influenza Vaccines: Lessons From the 1918 Pandemic.

Autor(es): Morens, David M; Taubenberger, Jeffery K
Fonte: J Infect Dis;219(Suppl_1): S5-S13, 2019 04 08.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 30715352
Resumo: The year 2018 marked the 100th anniversary of the deadliest event in human history. In 1918-1919, pandemic influenza spread globally and caused an estimated 50-100 million deaths associated with unexpected clinical and epidemiological features. The descendants of the 1918 virus continue to circulate as annual epidemic viruses causing significant mortality each year. The 1918 influenza pandemic serves as a benchmark for the development of universal influenza vaccines. Challenges to producing (mais)
Resultados  1-12 de 374